IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

AGENO, WALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 54.535
EU - Europa 25.267
AS - Asia 17.942
SA - Sud America 2.075
AF - Africa 339
Continente sconosciuto - Info sul continente non disponibili 56
OC - Oceania 27
Totale 100.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 54.045
IT - Italia 11.741
SG - Singapore 5.946
UA - Ucraina 4.101
CN - Cina 3.479
TR - Turchia 2.848
VN - Vietnam 2.466
HK - Hong Kong 2.145
DE - Germania 1.853
SE - Svezia 1.850
BR - Brasile 1.736
IE - Irlanda 1.239
GB - Regno Unito 1.014
FR - Francia 994
FI - Finlandia 975
RU - Federazione Russa 852
IN - India 290
MX - Messico 227
CA - Canada 205
BD - Bangladesh 154
AR - Argentina 118
NL - Olanda 113
AT - Austria 108
JP - Giappone 107
NG - Nigeria 98
IQ - Iraq 95
PL - Polonia 92
ES - Italia 91
ZA - Sudafrica 82
EC - Ecuador 55
EU - Europa 53
PK - Pakistan 51
SA - Arabia Saudita 50
BE - Belgio 45
UZ - Uzbekistan 39
ID - Indonesia 38
CO - Colombia 37
CZ - Repubblica Ceca 34
MA - Marocco 34
VE - Venezuela 34
LT - Lituania 30
AE - Emirati Arabi Uniti 29
CL - Cile 28
EG - Egitto 24
KE - Kenya 23
PY - Paraguay 23
JO - Giordania 22
MY - Malesia 22
PH - Filippine 22
AU - Australia 21
CH - Svizzera 19
DZ - Algeria 19
TN - Tunisia 17
BO - Bolivia 15
PT - Portogallo 15
RO - Romania 15
UY - Uruguay 15
TW - Taiwan 14
PE - Perù 12
GR - Grecia 11
IL - Israele 11
IR - Iran 11
AL - Albania 10
CR - Costa Rica 10
KZ - Kazakistan 10
KR - Corea 9
LB - Libano 9
NP - Nepal 9
PS - Palestinian Territory 9
TT - Trinidad e Tobago 9
HU - Ungheria 8
JM - Giamaica 8
OM - Oman 8
SN - Senegal 8
AZ - Azerbaigian 7
DK - Danimarca 7
MK - Macedonia 7
NO - Norvegia 7
BG - Bulgaria 6
CI - Costa d'Avorio 6
RS - Serbia 6
ET - Etiopia 5
GT - Guatemala 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
QA - Qatar 5
TH - Thailandia 5
AM - Armenia 4
AO - Angola 4
BA - Bosnia-Erzegovina 4
DO - Repubblica Dominicana 4
GE - Georgia 4
HR - Croazia 4
LK - Sri Lanka 4
PA - Panama 4
BB - Barbados 3
BN - Brunei Darussalam 3
BS - Bahamas 3
BY - Bielorussia 3
CG - Congo 3
Totale 100.182
Salva come PNG Salva come JPEG
Città #
Milan 8.511
Fairfield 7.198
Woodbridge 4.799
Ashburn 4.519
Houston 3.557
Jacksonville 3.302
San Jose 3.294
Singapore 3.168
Seattle 2.802
Wilmington 2.630
Cambridge 2.459
Ann Arbor 2.425
Chandler 2.236
Hong Kong 2.113
Dallas 1.545
Izmir 1.397
Princeton 1.350
Dublin 1.229
The Dalles 985
Dearborn 961
Boardman 832
Dong Ket 683
Nyköping 664
Beijing 651
Lauterbourg 639
Rome 633
Chicago 631
San Diego 398
Ho Chi Minh City 390
Los Angeles 337
San Mateo 308
New York 288
Ogden 261
London 258
Hanoi 239
Helsinki 228
Santa Clara 213
Council Bluffs 198
Como 190
Guangzhou 184
São Paulo 177
Washington 164
Munich 153
Mexico City 144
Düsseldorf 139
Orem 130
Hefei 127
Redmond 122
Nanjing 105
Nuremberg 97
Tokyo 97
Abuja 92
Frankfurt am Main 88
Kocaeli 88
Shanghai 87
Chennai 83
Kunming 83
Verona 81
Norwalk 75
Warsaw 75
Montreal 70
Phoenix 70
Salt Lake City 70
Hangzhou 69
Brooklyn 64
Tianjin 63
Buffalo 62
Shenzhen 60
Stockholm 59
Amsterdam 58
San Francisco 58
Jinan 57
Nanchang 57
Haiphong 55
Turku 55
Rio de Janeiro 53
Boston 52
Da Nang 50
Manchester 50
Toronto 50
Columbus 49
Denver 49
Atlanta 48
Tampa 48
Elk Grove Village 46
Zhengzhou 46
Belo Horizonte 45
Johannesburg 45
Vienna 44
Kilburn 39
Philadelphia 39
Brussels 38
Falls Church 38
Fuzhou 35
Tashkent 34
Besana In Brianza 33
Mumbai 32
Curitiba 30
Baghdad 29
Changsha 29
Totale 72.890
Salva come PNG Salva come JPEG
Nome #
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts 401
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 310
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 307
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 297
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 291
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 290
Abdominal obesity and the risk of recurrent deep vein thrombosis 270
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 265
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 262
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 262
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 260
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 256
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 254
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 252
Risk of recurrence of unusual site venous thromboembolism 252
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 250
Optimal treatment duration of venous thrombosis 247
ABO blood group and vascular disease: an update 247
Management of recurrent venous thromboembolism in cancer patients 246
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 244
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 242
Breadth of complications of long-term oral anticoagulant care 241
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 235
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 233
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 232
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 231
Warfarin interactions with antibiotics in the ambulatory care setting 230
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 230
Prevention and treatment of venous thromboembolism 229
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 228
A new era for venous thromboembolism prevention in medical inpatients 228
Venous ischemic syndromes 228
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 227
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 227
Exaggerated initial response to warfarin following heart valve replacement 225
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 225
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 225
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 223
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 223
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 221
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 220
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment 219
Oral rivaroxaban for symptomatic venous thromboembolism 217
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 217
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 216
Applying EBM in clinical practice 215
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 215
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. 215
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 215
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 215
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 215
Patient selection for thromboprophylaxis in medical inpatients 214
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 212
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 212
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 212
Abdominal obesity and the risk of recurrent deep vein thrombosis. 211
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 211
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 210
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 210
Venous and arterial thrombosis in patients with HIV infection 209
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 209
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 209
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 208
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 207
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 207
Venous thromboembolism: Past, present and future 207
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 206
Management of incidental splanchnic vein thrombosis in cancer patients 206
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 206
A survey of thromboprophylaxis management in patients with major trauma. 205
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 205
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 205
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 204
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 204
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 204
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 204
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 203
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study 203
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality 202
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 202
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 201
Managing challenging patients with venous thromboembolism: A practical, case-based approach 201
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 201
Duration of anticoagulation after venous thromboembolism in real world clinical practice 200
Statins, fibrates, and venous thromboembolism: a meta-analysis. 199
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 198
Guidance for the management of venous thrombosis in unusual sites 198
Treating patients with cancer and acute venous thromboembolism 197
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation 196
Direct oral anticoagulants in rare venous thrombosis 196
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 196
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. 195
Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. 195
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal 195
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 195
Statins and secondary prevention of ischemic and hemorrhagic stroke 194
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding 194
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists 194
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 193
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 193
Totale 22.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 414.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 414.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.353 0 0 0 0 0 0 0 0 0 803 953 1.597
2021/20226.828 757 872 355 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20259.742 69 75 1.781 238 230 684 403 654 1.099 820 967 2.722
2025/202620.791 1.428 1.409 1.478 2.721 1.762 1.425 5.181 1.401 2.969 1.017 0 0
Totale 101.134